Technical View- Kanger International Bhd - Rakuten Trade Research Reports | I3investor
Technical View- Kanger International Bhd Author: rakutentrade Publish date: Tue, 1 Dec 2020, 11:53 AM
Kanger International Bhd (0170) • KANGER dropped 2.7% or 0.5 sen to RM0.18 yesterday.
• Chart-wise, share price has been in consolidation mode for some time with trading volume improving of late showing signs of stealth buying pattern. News of the company signing collaboration agreement Sinopharm to distribute Covid-19 vaccine and has received support from Ministry of Science, Technology and Innovation is likely to spur buying interest as one of the potential vaccine-play stocks.
• From here, resistance levels are expected at RM0.195 (R1) and RM0.230 (R2) level.
• On the downside, support levels are set at RM0.160 (S1) and RM0.120 (S2).
you are at the mercy of the shark. The shark want it up it will up. The shark want it down nothing you can do also. vaccine is just an excuse for the shark to goreng the ctr only. correct?
If Pfizer vacc is good, then why dont it try to be used in America first as Clinical trial phase 3.. i was so stunned ...even before FDA approve or even our KKM abd NPRA validate.... Some quarters authority already sign agreement of purchase..somnething irrational ...
The answer is not always correct. One more scenerio. shark want down. you collect. shark make it even lower. all stuck inside. cry apah. cry amah. also no one will help.
purple_rain The shark want it up, sell to the shark. The shark want it down, buy from the shark. Correct? 01/12/2020 6:34 PM
The revelations in the paper by researchers from the CDC reinforce the growing understanding that the coronavirus was silently circulating worldwide earlier than known, and could re-ignite debate over the origins of the pandemic.
It’s not the first evidence showing the virus could have existed or infected people outside China before 2020. A patient in France was found to have contracted the virus after being hospitalized with flu-like symptoms at the end of December, contradicting official statistics showing Covid-19 reached the country from people returning from Wuhan at the end of January.
The CDC study indicated there were isolated infections in the western part of the U.S. in mid-December. Antibodies were also found in early January in other states before the virus was known to have been introduced to those places.
The scientists indicated it’s unlikely that the antibodies developed to curb other coronaviruses, as 84 samples were found to have neutralizing activity specific to SARS-CoV-2.
Yes, would think 0.16 is a good bet. But chartwise, it may just turn and head towards 0.20. As it is, the sentiment is damp - left hand sell, right hand buy, and repeat
• Chart-wise, share price has been in consolidation mode for some time with trading volume improving of late showing signs of stealth buying pattern. News of the company signing collaboration agreement Sinopharm to distribute Covid-19 vaccine and has received support from Ministry of Science, Technology and Innovation is likely to spur buying interest as one of the potential vaccine-play stocks.
• From here, resistance levels are expected at RM0.195 (R1) and RM0.230 (R2) level.
• On the downside, support levels are set at RM0.160 (S1) and RM0.120 (S2).
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Carefully
121 posts
Posted by Carefully > 2020-12-01 18:05 | Report Abuse
Technical View- Kanger International Bhd - Rakuten Trade Research Reports | I3investor
Technical View- Kanger International Bhd
Author: rakutentrade Publish date: Tue, 1 Dec 2020, 11:53 AM
Kanger International Bhd (0170)
• KANGER dropped 2.7% or 0.5 sen to RM0.18 yesterday.
• Chart-wise, share price has been in consolidation mode for some time with trading volume improving of late showing signs of stealth buying pattern. News of the company signing collaboration agreement Sinopharm to distribute Covid-19 vaccine and has received support from Ministry of Science, Technology and Innovation is likely to spur buying interest as one of the potential vaccine-play stocks.
• From here, resistance levels are expected at RM0.195 (R1) and RM0.230 (R2) level.
• On the downside, support levels are set at RM0.160 (S1) and RM0.120 (S2).
Source: Rakuten Research - 1 Dec 2020